Dear all: Happy New Year! The tiger year is revitalized, the rabbit year welcomes the prosperous world and starts a new journey! Its time to welcome the new year again, on behalf of all the staff of our company, I would like to wish you a happy New Year! I wish you family reunion, happiness and health, and all the best!
Shanghai, China, January 19, 2023 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that Zhongxin Medical Technology Co., Ltd. ("Zhongxin"), one of the China operating entities of which the Company consolidates the financial results with through certain contractual arrangements, launched the Medication Management Assistance Mini Program on WeChat (the “Program”) to assist cancer patients in managing multiple issues during the medication and facilitate whole treatment process.
Shanghai, China, January 4, 2023 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang Pharmaceutical"), one of the Chinese operating entities of which the Company consolidates the financial results with through certain contractual arrangements, will act as the drug distribution agent of certain drugs produced by Natco Pharma Limited (“Natco”) within Mainland China pursuant to certain agreements. Natco is a vertically integrated and R&D focused pharmaceutical company in India.
Shanghai, China, December 5, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that after three years of preparation, the Company’s MDMOOC platform has established a “Surgical-Interventional-Drug” (“SID”) platform for liver cancer comprehensive-disciplinary physician education (“SID Platform”), providing physicians with knowledge and techniques in comprehensive-disciplinary comprehensive management of patients with liver cancer.
Shanghai, China, November 3, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that one of the China operating entities of which the Company consolidates the financial results with through certain contractual arrangements, Chongqing Xinjiang Pharmaceutical Co., Ltd. (“Xinjiang Pharmaceutical”) has obtained a series of pharmaceutical related licenses, which lay a solid foundation for Zhongchao to develop pharmaceutical services and expand to the pharmaceutical market. The Company believes that the operation of Xinjiang Pharmaceutical will further strengthen the upgraded “Medical-Pharmaceutical-Patient” model.
SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the establishment of Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang Pharmaceutical") which mainly engages in pharmaceutical import and export trade, OME (original equipment manufacturer) production, medical consumables operation, and pharmaceutical internet services. Zhongchao expects to further improve and complement its business model of "Medical-Pharmaceutical-Patient" as Xinjiang Pharmaceutical plays an important role in supplying quality medications for patients.
Shanghai, China, September 15, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced that its subsidiary, Zhixun Internet Hospital (Liaoning) Co., Ltd., launched Zhixun Internet Hospital to provide standardized Internet healthcare services for patients with oncology or other major diseases. It is another important step for Zhongchao to further improve its patient management services in the field of oncology and major diseases.
SHANGHAI, Sept 1, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated experiences in medical education and innovation, and extensive resources with medical professionals and pharmaceuticals, Zhongchao is well positioned to become a platform that provides patients with major disease management services.
Shanghai, China, June 13, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its MDMOOC platform launched online training course (the “Course”) titled “Disease Prevention and Distribution Quality Management,” to staffs (the “Staffs”) in various departments for diseases control and prevention, in order to improve their skillsets and efficiency in vaccination management as well as diseases control and prevention.
SHANGHAI, Oct. 29, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced its self-developed patient management system improves Duration of Therapy ("DOT") by 40.4% for liver cancer patients, which contributes to the maximum efficiency of drugs, successful treatment and longer patient survival terms.